1. At a Glance (50 words)
3B BlackBio Dx (formerly Kilpest India) is acquiring 100% of Belgium’s Coris Holding SRL for £2.765M (cash + earnout). Coris specializes in antimicrobial resistance (AMR) diagnostics with €5.2M revenue. This cross-border move adds rapid test tech and European presence to 3B’s portfolio. Investors smell a global play.
2. Intro – Why This Matters
From Bhopal to Belgium, 3B just leveled up. Coris is a European pioneer in AMR rapid tests and lateral flow assays. This acquisition means access to global markets, R&D synergies, and expansion beyond PCR. For 3B, it’s not just buying a company—it’s buying a
